Editorial
PIVOT and the challenges of localized prostate cancer care
Translational Andrology and Urology
2012;
1
(3)
:141-143
.
(17 September 2012)
New prognostic models in metastatic renal cancer
Translational Andrology and Urology
2012;
1
(3)
:144-145
.
(17 September 2012)
Interpretation of PIVOT findings
Translational Andrology and Urology
2012;
1
(3)
:146-147
.
(17 September 2012)
Original Article
Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Translational Andrology and Urology
2012;
1
(3)
:148-152
.
(17 September 2012)
Review Article
Vesicoureteral reflux and bladder dysfunction
Translational Andrology and Urology
2012;
1
(3)
:153-159
.
(17 September 2012)
Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences
Translational Andrology and Urology
2012;
1
(3)
:160-172
.
(17 September 2012)
Regenerative technology for future therapy of erectile dysfunction
Translational Andrology and Urology
2012;
1
(3)
:173-180
.
(17 September 2012)
Phytotherapy: emerging therapeutic option in urologic disease
Translational Andrology and Urology
2012;
1
(3)
:181-191
.
(17 September 2012)
Research Highlight
Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
Translational Andrology and Urology
2012;
1
(3)
:192-193
.
(17 September 2012)
The complexity of sunitinib dosing in renal cell cancer patients
Translational Andrology and Urology
2012;
1
(3)
:194-196
.
(17 September 2012)
Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
Translational Andrology and Urology
2012;
1
(3)
:197-198
.
(17 September 2012)
